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RESEARCH LETTER
Tamoxifen Acts as a
Parietal Cell
Protonophore
Oxyntic atrophy, the loss of gastric
parietal cells, is a critical precursor
of metaplasia in the stomach. In the
case of humans, Helicobacter pylori
infection induces loss of parietal
cells from the corpus of the stomach
over years, while 6–12 months of
Helicobacter infection is required to
induce oxyntic atrophy in rodents.1
In mice, acute models of parietal
cell loss have helped distinguish key
steps in the induction of chief cell
reprogramming into metaplasia.
These studies initially used the drug
DMP-777, which was demonstrated
to function as a parietal cell secre-
tory membrane protonophore using
assay of H/K-ATPase–dependent
proton gradients in isolated rabbit
tubulovesicles.2 DMP-777 did not
directly inhibit the proton pump ac-
tivity. Treatment with DMP-777
caused rapid parietal cell loss in
both mice and rats over 3 days,
leading to development of spasmo-
lytic polypeptide-expressing meta-
plasia.2,3 Pretreatment of rats with
proton pump inhibitors blunted the
ability of DMP-777 to induce oxyntic
atrophy.4 Similar findings were seen
for a number of molecular cousins of
DMP-777, including L635.5 While
DMP-777 induces oxyntic atrophy
without a prominent immune
response, because of its coordinate
action as a neutrophil elastase in-
hibitor, L635 lacks this action
against elastase and elicits parietal
cell loss and an exuberant immune
response.5
In more recent years, other
studies have demonstrated the ability
of tamoxifen administration (espe-
cially intraperitoneal doses of 5 mg
or greater) to also induce parietal cell
loss.6 As with DMP-777, pretreat-
ment of mice with proton pump in-
hibitors ameliorated the effects of
tamoxifen to induce parietal cell
loss.6 However, no studies have
directly assayed the effects of
tamoxifen as a parietal cell proto-
nophore. We have therefore sought to
compare the effects of tamoxifen with
those of DMP-777 and L635 on acid
sequestration in parietal cell
tubulovesicles.
Parietal cell tubulovesicles were
isolated from rabbit stomach mucosa
using standard protocols and tubulove-
sicles layering above 20% sucrose in
gradient centrifugation were utilized as
the tightest tubulovesicle membranes
(see supplementary methods).7 The
fluorescence of acridine orange was
assayed in tubulovesicles using induc-
tion of pumping in the presence of
adenosine triphosphate and valinomy-
cin. Activation of acid pumping into
tubulovesicles causes a rapid quenching
of acridine orange fluorescence indica-
tive of pumping of acid into the lumen
of tubulovesicles (Figure 1). After the
establishment of the proton gradient in
tubulovesicles, tamoxifen, DMP-777, or
L635 were added in concentrations
from 0.1 to 10 mM and effects on the
quenching of acridine orange were
assayed (Figure 1). At concentrations
from 1 to 10 mM, all 3 drugs caused a
rapid decrease in acridine orange fluo-
rescence, indicative of disruption of the
proton gradient. These findings sug-
gested that all 3 drugs act similarly as
protonophores in parietal cell acid
secretory membranes.
The results in these studies
confirm that tamoxifen does act as a
parietal cell protonophore, which can
lead to back wash of acid into
secreting parietal cells, the likely
cause of parietal cell death following
administration of high-dose tamox-
ifen. The potency of tamoxifen as a
parietal cell protonophore is similar
to that both DMP-777 and L635. It
should be noted that a number of
hydrophobic drugs with properties of
weak bases may have parietal cell
protonophore activities. KN-93, which
has been utilized as an inhibitor of
calmodulin-dependent protein kinase
II, has a strong protonophore effect
on parietal cells.8 Nevertheless, it
should be noted that these
protonophore actions require
extremely high doses of drug that are
usually greater than an order of
magnitude higher than doses used for
treating patients.6
Nevertheless, because tamoxifen-
inducible Cre recombinase strains
are commonly used, especially to
track stem cell activity, it is critical to
recognize that tamoxifen can kill pa-
rietal cells, triggering adaptive, non-
homeostatic patterns of proliferation
in the stomach. A recent report by
Samuelson et al9 has highlighted the
dose dependence of tamoxifen action
in the stomach. That report noted a
gap in the knowledge of the precise
mechanism of tamoxifen action
related to oxyntic atrophy leading us
to perform the present studies. It is
notable that the effects of tamoxifen
to induce parietal cell loss, as well as
the recovery from tamoxifen, were
not dependent on gastrin. Similar re-
sults were previously observed with
DMP-777 administration.3 Thus,
cholinergic stimulation in these ani-
mals may be adequate to maintain
sufficient acid secretion and lead to
acute parietal cell loss. While tamox-
ifen, DMP-777, and L635 all possess a
parietal cell protonophore capacity, it
remains unclear as to whether their
off-target effects may differ. It is clear
that these 3 models of acute oxyntic
atrophy all differ in the range of in-
flammatory reactions they incite.
Given the recent evidence for the
roles of immune cells in promoting
the induction and progression of
metaplasia,10 each of these models
needs to be evaluated in detail, and in
comparison with more chronic forms
of oxyntic atrophy.
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Figure 1. Assay of acridine orange
fluorescence in isolated tubulove-
sicles treated with tamoxifen, DMP-
777, or L635. Isolated rabbit gastric
tubulovesicles were incubated with acri-
dine orange, and initiation of the proton
pumping gradient was activated with
addition of valinomycin and adenosine
triphosphate (first black arrowhead).
Control (no addition), vehicle solutions,
or drugs were then added at the indi-
cated concentrations after 15 minutes
(second black arrowhead) and
dequenching was analyzed for 20 min.
The traces (± SD) represent representa-
tive experiments from 4 separate
analyses. (A) Tamoxifen response. (B)
DMP-777 response. (C) L635 response.
(D) Comparison of tamoxifen, DMP-777,
and L635 response at 10 mM. Note that
dimethyl sulfoxide (DMSO) vehicle con-
trol samples showed a small baseline
adjustment likely due to the time required
for addition of drugs.
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Supplementary Table 1.Formulation of Test Compounds
Control or sample name
(reagent added at time
point 3)
Control or sample
details
Reagent
storage stock
Reagent solution prepared
for assay
Final reagent
concentration
in assay well
Diluent only Negative control for
assay
Acridine orange diluent
DMSO Negative control for
DMP-777, L635,
and tamoxifen
2.5% DMSO in acridine
orange diluent
0.25%
DMP-777 Positive control 10 mM in DMSO 100 mM in acridine orange
diluent
10, 3, or 1 mM
L635 Positive control 11 mM in DMSO 100 mM in acridine orange
diluent
10, 3, or 1 mM
Tamoxifen Sample 4 mM in DMSO 100 mM in acridine orange
diluent
10, 3, 1, 0.3, or
0.1 mM
DMSO, dimethyl sulfoxide.
Supplementary Materials
and Methods
Materials
DMP-777 was a gift of DuPont-Merck
Corporation (North Billerica, MA).
L635 was synthesized in the Vander-
bilt Chemical Biology Shared Resource
and was validated as a single enan-
tiomeric compound of >99.5% purity.
Tamoxifen was obtained from Sigma-
Aldrich (St. Louis, MO). All other
compounds were obtained from
Sigma-Aldrich.
Preparation of Rabbit Gastric
Tubulovesicles
Rabbit tubulovesicles were prepared
from homogenized gastric mucosa by
differential centrifugation followed
by sucrose gradient velocity sedi-
mentation, as previously described.1
Tubulovesicle membranes that floa-
ted on the 20% sucrose cushion
were utilized as high-resistance
tubulovesicles.
Assay of Acridine Orange
Accumulation Into
Tubulovesicles
Assay master mix was composed of 1.2-
mM acridine orange/290-mM adenosine
triphosphate/24 mg/mL tubulovesicles
froma freshly thawedaliquot in acridine
orange diluent (150-mM sucrose/75-
mM KCl/250-mM MgSO4/5-mM pipera-
zine-N,N0-bis(2-ethanesulfonic acid)/5-
mM Tris, pH 7). Valinomycin was
diluted to 20 mM in acridine orange
diluent from a 0.9-mM stock in dimethyl
sulfoxide. Control and sample assay re-
agents were diluted as described in
Supplementary Table 1.
Master mix (85 mL) was added to
wells in a 96-well microtiter plate in
quadruplicate for each control or sam-
ple. The plate was read (time point 1)
using a BioTek Synergy 4 (BioTek,
Winooski, VT) plate reader at 493-nm
excitation/530-nm emission once per
minute for 3 minutes at ambient tem-
perature, then ejected. Valinomycin (5
mLof 20-mMsolution)was added to each
well to a final concentration of 1 mM
(time point 2), then the platewas shaken
for 5 seconds and read for 10 more mi-
nutes and ejected. Control and sample
reagents diluted in acridine orange
diluent (10 mL each) were added to the
wells to the final concentrations
described in Supplementary Table 1
(time point 3). The total volume in each
well after time point 3 was 100 mL. The
plate was shaken for 5 seconds and read
for at least 15 more minutes.
Data Analysis
Raw absorbance data for each well
were converted to fold change by
dividing all absorbance readings by the
first absorbance reading using Google
Sheets. Fold-change means and stan-
dard deviations for each control and
sample across the quadruplicates were
also calculated. Figures were made
using Open Office Calc (Apache Soft-
ware Foundation, Forest Hill, MD).
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